AstraZeneca Says Forxiga Approved in China for Chronic Kidney Disease
05 September 2022 - 8:55AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Monday that its Forxiga drug has been
approved in China for the treatment of chronic kidney disease, or
CKD, in patients at risk of progression with and without type-2
diabetes.
The Anglo-Swedish pharma giant said the approval was based on
positive results from the DAPA-CKD phase 3 trial.
The company said that Forxiga, also known as Farxiga in the
U.S., was now approved in 100 countries around the world including
the U.S., the EU and Japan for the treatment of chronic kidney
disease in adults with and without T2D.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 05, 2022 02:40 ET (06:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024